Phase 3 Crohn's Disease and Colitis Trial, Completed NCT01008410 Sponsor: Bausch Health Americas, Inc. Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 265 adults — 133 in the budesonide group and 132 in the placebo group. The trial was measuring how a medicine called budesonide compared to a dummy treatment (placebo) in people with ulcerative colitis. The main thing being measured was whether participants reached "remission" after six weeks — a combined assessment based on a colonoscopy score, the absence of rectal bleeding, and no worsening of how often they needed the toilet, all scored using a standard disease activity index. The reported data shows that after six weeks, 38.3% of participants in the budesonide group and 25.8% in the placebo group met the remission criteria. For the secondary measures, the reported figures were: no visible rectal bleeding at week 6 — 46.6% (budesonide) vs 28.0% (placebo); normal or only mildly abnormal colonoscopy score — 55.6% vs 43.2%; a combined symptom score meeting a specific low threshold — 41.4% vs 25.8%; and an overall disease score of 3 or less with meaningful improvement from the starting point — 45.9% vs 30.3%. The reported data also shows percentages of participants who had no rectal bleeding at various scheduled check-ins during the treatment period, ranging from roughly 6% to 21% in the budesonide group and 1.5% to 13.6% in the placebo group across those time points. It is worth noting that not everyone finished the trial — 108 of 133 people in the budesonide group and 116 of 132 in the placebo group completed it, and the reasons for not completing were not detailed in the data provided here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 3 Crohn's Disease and Colitis Trial, Completed

NCT01008410
Completed Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a written consent form to participate.
  • You are male, or a female who is not pregnant or breastfeeding.
  • You have been confirmed by a camera procedure (endoscopy) to have active, mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis, with the affected area reaching at least 5 cm but no more than 40 cm from the opening of the rectum.
  • Your disease activity score on a specific medical scale falls between 5 and 10 at the start of the trial (confirm with trial site).

Who may not be able to join:

  • You have been diagnosed with, or have a history of, Crohn's disease or indeterminate colitis.
  • You have had previous bowel or stomach surgery, except for appendix removal or hernia repair.
  • You currently have another active digestive condition or an abnormal bowel structure.
  • You have a history of diverticulitis, collagenous colitis, celiac disease, recurring pancreas problems, or known gallbladder disease.
  • You have type 1 or type 2 diabetes that is not well controlled.
  • You have a thyroid condition that is not well controlled.
  • You have an unstable or serious heart, hormonal, neurological, or lung condition.
  • Your blood count shows a haemoglobin level below 7.5 g/dL, indicating significant anaemia (confirm with trial site).
  • You have a history of a specific liver condition called sclerosing cholangitis, liver scarring (cirrhosis), or reduced liver function.
  • You have kidney disease shown by a specific blood test result above a certain level (confirm with trial site).
  • You have a history of a specific hip bone condition, active tuberculosis, certain eye infections caused by herpes or chickenpox viruses, any cancer, or HIV, hepatitis B, or hepatitis C.
  • You have a condition where your adrenal glands do not produce enough hormones.
  • You currently have a serious infection anywhere in the body or skin, or serious bowel complications such as a severely swollen colon, a fistula, a hole in the bowel, or an abscess.
  • You have a history of a mental health condition or seizure disorder that is not well controlled.
  • You have a history of asthma that requires regular use of inhaled steroid medication.
  • You have recently had problems with drug or alcohol misuse.
  • Your stool test has come back positive for certain bacteria, a toxin called Clostridium difficile, or parasites.
  • You have received a vaccination within 28 days before joining the trial.
  • You have an allergy to budesonide (the study drug) or any of its ingredients.
  • You have taken part in another clinical trial within the past 30 days.
  • You are pregnant or there is a chance you could become pregnant during the trial.
  • You are currently taking certain medications that are not allowed during the trial, including laxatives and anti-diarrhoea medicines, certain antibiotics, anti-seizure medications, and blood-thinning medications (some medicines are permitted — confirm the full list with the trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Bausch Health Americas, Inc.
Registry
ClinicalTrials.gov
Start date
17 November 2009
Est. completion
29 April 2013

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of Participants Who Achieved Remission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov